MGLL and central nervous system disorder: Therefore, the present work concluded that compound 20 is the potential lead compounds that can be further manipulated at points 1 and 4 of the 2-pyrrolidinone moiety for the discovery and development of more selective and potent inhibitors of MAGL for neuropathic pain and CNS disorders including cancers.